Clinical and Translational Gastroenterology now has an Impact Factor and makes its debut at a noteworthy 3.472*
By David C. Whitcomb, MD, PhD, FACG, University of Pittsburgh Medical Center
*2015 Journal Citation Reports® Science Edition (Thomson Reuters, 2016)
CTG’s Inaugural Impact Factor
ACG is pleased to announce that Clinical and Translational Gastroenterology has received a 2015 Impact Factor of 3.472*, making it the top-ranked open access journal in gastroenterology and hepatology! This is an important achievement that would not be possible without the time and efforts of the editors, authors and reviewers. Thank you all for your support!
CTG hopes to fulfill an unmet need for clinicians and scientists by welcoming novel case series and cohort studies, early-phase clinical trials, qualitative and quantitative epidemiologic research, hypothesis-generating research, studies of novel mechanisms and methodologies including public health interventions, and integration of approaches across organs and disciplines.
Meet the CTG Editorial Board
Associate Editors
Barbara Jung, MD
Division of Gastroenterology and Hepatology
University of Illinois College of Medicine at Chicago
Chicago, IL
Florian Rieder, MD
Department of Gastroenterology, Hepatology & Nutrition
Cleveland Clinic Foundation
Cleveland, OH
Amit Singal, MD
Department of Clinical Science
UT Southwestern Medical Center
Dallas, TX
Outgoing Associate Editor
Ashwin Ananthakrishnan, MBBS, MPH
Division of Clinical Research
Massachusetts General Hospital
ACG and CTG sincerely thank Ashwin Ananthakrishnan, MBBS, MPH, for his service as CTG Associate Editor from 2014 to 2016. His dedication and expertise were integral to the success of the Journal.
Editor’s Picks by Dr. David Whitcomb
Noteworthy in 2016 from Clinical and Translational Gastroenterology
The Effects of Bowel Preparation on Microbiota-Related Metrics Differ in Health and in Inflammatory Bowel Disease and for the Mucosal and Luminal Microbiota Compartments
Rima M Shobar, Suresh Velineni, Ali Keshavarzian, Garth Swanson, Mark T DeMeo, Joshua E Melson, John Losurdo, Philip A Engen, Yan Sun, Lars Koenig and Ece A Mutlu
Clin Trans Gastroenterol 7: e143; doi:10.1038/ctg.2015.54
This study demonstrated that the human biome is markedly altered by gut lavage as in preparation for a colonoscopy. Importantly for inflammatory bowel disease (IBD), the healthy bacteria that reside in the gut lumen are generally reduced in amount, with smaller effects on bacteria adherent to the mucosa such as bactericides — a species associated with pathology in IBD. These findings implicate important variables for biome research methodology, and suggest that bowel prep may contribute to emergence of a more pathogenic microbiome milieu in some patients.
Lower Gastrointestinal Bleeding And Risk of Gastrointestinal Cancer
Søren Viborg, Kirstine Kobberøe Søgaard, Dóra Körmendiné Farkas, Helene Nørrelund, Lars Pedersen and Henrik Toft Sørensen
Clin Trans Gastroenterol 7: e162; doi:10.1038/ctg.2016.16
This nationwide cohort study from Denmark evaluated the risk of various GI cancer types in patients with their first hospitalization for lower GI bleeding. Subjects were followed for 10 years. During the first year of follow-up, the absolute GI cancer risk was 3.6%, with the standardized incidence ratio (SIR) of any GI cancer at 16.3. The majority of cancers were colorectal, and the risk dropped for all cancers over five years except for liver and pancreatic cancer.
Blood and Intestine eQTLs from an Anti-TNF-Resistant Crohn’s Disease Cohort Inform IBD Genetic Association Loci
Antonio F Di Narzo, Lauren A Peters, Carmen Argmann, Aleksandar Stojmirovic, Jacqueline Perrigoue, Katherine Li, Shannon Telesco, Brian Kidd, Jennifer Walker, Joel Dudley, Judy Cho, Eric E Schadt, Andrew Kasarskis, Mark Curran, Radu Dobrin and Ke Hao
Clinical and Translational Gastroenterology (2016) 7, e; doi:10.1038/ctg.2016.34
Patients from an IBD clinical trial who failed anti-TNF therapy were evaluated for genetic variants associated with altered gene expression in blood (leukocytes) and intestinal mucosa. Distinct patterns were identified that overlapped other inflammatory diseases in some cases, but others that were more specific to IBD. The findings bring insights into the mechanisms underlying IBD by linking specific genetic variants with predictable changes in proteins within key tissues and systems.
Comparative Proteomic Analysis of Whole-Gut Lavage Fluid and Pancreatic Juice Reveals a Less Invasive Method of Sampling Pancreatic Secretions
Jana M Rocker, Marcus C Tan, Lee W Thompson, Carlo M Contreras, Jack A DiPalma and Lewis K Pannell
Clin Trans Gastroenterol 7: e174; doi:10.1038/ctg.2016.27
This study describes a novel approach to assessing pancreatic exocrine function that is potentially simple, powerful and possibly suitable to screen for some types of pancreatic diseases. Pancreatic proteins were found in whole gut lavage fluid (WGLF), which is the fluid from oral bowel preparation for colonoscopy. Surprisingly, two thirds of the proteins in this fluid is of pancreatic origin! Furthermore, because of the gut lavage process, most of the other exogenous components of human stool have been eliminated. Using LC-MS/MS, the authors demonstrate that pancreatic proteins could be identified and quantified in a reliable and reproducible way, and that their findings roughly matched the findings of others using more-invasive methods. This could be a very exciting and potentially powerful approach to more-comprehensive measures of biomarkers of pancreatic exocrine secretory function.
Do you have a manuscript that may be good for CTG?
Please read our guide to authors and submit to our manuscript site today. Submission is free and discounted author processing charges are available for ACG members as well as manuscripts transferred from The American Journal of Gastroenterology. Contact Lindsey Topp in the editorial office with questions: ltopp@gi.org